Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
← catalyst calendarSponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Gilead Sciences.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
151actual
Sites
44
Countries
Australia, Canada, Hong Kong +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-05-28 | actual | When the study began enrolling |
| Primary completion | 2025-07-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2020-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer
Interventions
- Drug: Domvanalimab — also filed as AB154
- Drug: Etrumadenant — also filed as AB928
- Drug: Zimberelimab — also filed as AB122
Primary outcomes
what the primary-completion date above is the date OFObjective response rate (ORR)
measured From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Progression-free survival (PFS)
measured From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed